Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Regenxbio (RGNX) Interest Expenses (2021 - 2025)

Regenxbio has reported Interest Expenses over the past 7 years, most recently at $12.3 million for Q4 2025.

  • Quarterly results put Interest Expenses at $12.3 million for Q4 2025, up 30.36% from a year ago — trailing twelve months through Dec 2025 was $45.0 million (up 255.54% YoY), and the annual figure for FY2025 was $45.0 million, up 255.54%.
  • Interest Expenses for Q4 2025 was $12.3 million at Regenxbio, down from $13.2 million in the prior quarter.
  • Over the last five years, Interest Expenses for RGNX hit a ceiling of $13.2 million in Q3 2025 and a floor of $449000.0 in Q2 2024.
  • Median Interest Expenses over the past 5 years was $6.2 million (2021), compared with a mean of $5.7 million.
  • Biggest five-year swings in Interest Expenses: crashed 83.67% in 2023 and later surged 2348.33% in 2025.
  • Regenxbio's Interest Expenses stood at $6.5 million in 2021, then crashed by 33.69% to $4.3 million in 2022, then crashed by 68.38% to $1.4 million in 2023, then surged by 590.9% to $9.4 million in 2024, then surged by 30.36% to $12.3 million in 2025.
  • The last three reported values for Interest Expenses were $12.3 million (Q4 2025), $13.2 million (Q3 2025), and $11.0 million (Q2 2025) per Business Quant data.